A specialized clinical pathway for patients who fail standard SSRIs, utilizing high-dose psilocybin for rapid symptom reduction.
The PESTEL analysis reveals a high-potential clinical opportunity driven by strong technological efficacy and social demand, but one that is heavily constrained by legal and political hurdles. While the economic case is strong due to the high cost of TRD, the path to scale depends entirely on the rescheduling of psilocybin.
Political2
Economic3
Social2
Technological2
Environmental1
Legal2
The viability of psilocybin treatments is primarily driven by legal regulations, medical ethics, and societal acceptance of psychedelics. · Generated 2026-09-05 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated